Literature DB >> 9721941

5-HT1A receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test.

M Leone1, A Attanasio, D Croci, A Ferraris, D D'Amico, L Grazzi, A Nespolo, G Bussone.   

Abstract

Involvement of the cerebral serotoninergic system has been invoked to explain the origin of the pain and the vascular phenomena in migraine. To further investigate the type of cerebral serotonin receptors that may be altered in migraine, the prolactin (PRL) and cortisol responses to m-chlorophenylpiperazine (mCPP), a selective 5-HT1A,-5-HT(2A/C) receptor agonist, were monitored in 12 patients suffering from migraine without aura and in 14 matched healthy controls. Each subject underwent two challenges, one with mCPP (0.5 mg/kg) and the other with placebo (orally) using a double-blind crossover design. Anxiety level was measured by the State Trait Anxiety Inventory. Migraine patients had a greater PRL response to mCPP (p = 0.05) and greater anxiety (p < 0.01) than controls; cortisol response to mCPP did not differ suggesting that 5-HT2C receptors are normal in migraine. Augmented PRL response to mCPP could derive from 5-HT1A receptor hypersensitivity, perhaps as as a consequence of anxiety due to pain expectation. Cerebral 5-HT1A hypersensitivity could also explain the increased occurrence of migraine attacks during anxiety.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721941     DOI: 10.1097/00001756-199808030-00033

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  6 in total

Review 1.  The recombinant 5-HT1A receptor: G protein coupling and signalling pathways.

Authors:  J R Raymond; Y V Mukhin; T W Gettys; M N Garnovskaya
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Substitution of 5-HT1A receptor signaling by a light-activated G protein-coupled receptor.

Authors:  Eugene Oh; Takashi Maejima; Chen Liu; Evan Deneris; Stefan Herlitze
Journal:  J Biol Chem       Date:  2010-07-19       Impact factor: 5.157

3.  Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine.

Authors:  I Rainero; W Valfrè; L Savi; S Gentile; L Pinessi; L Gianotti; E Arvat; E Ghigo; P Del Rizzo; P Calvelli; P Limone
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

Review 4.  Preclinical neuropharmacology of naratriptan.

Authors:  Geoffrey A Lambert
Journal:  CNS Drug Rev       Date:  2005

Review 5.  Serotonin and migraine: a reconsideration of the central theory.

Authors:  Alessandro Panconesi
Journal:  J Headache Pain       Date:  2008-07-31       Impact factor: 7.277

6.  Dihydroergotamine and its metabolite, 8'-hydroxy-dihydroergotamine, as 5-HT1A receptor agonists in the rat brain.

Authors:  N Hanoun; F Saurini; L Lanfumey; M Hamon; S Bourgoin
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.